Wall Street Zen cut shares of Assembly Biosciences (NASDAQ:ASMB – Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Saturday morning.
ASMB has been the topic of several other reports. Guggenheim increased their target price on shares of Assembly Biosciences from $39.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, May 4th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Assembly Biosciences has an average rating of “Moderate Buy” and a consensus target price of $42.75.
View Our Latest Research Report on ASMB
Assembly Biosciences Price Performance
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. The firm had revenue of $8.21 million for the quarter, compared to the consensus estimate of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. As a group, sell-side analysts anticipate that Assembly Biosciences will post -0.93 earnings per share for the current year.
Institutional Investors Weigh In On Assembly Biosciences
Several hedge funds and other institutional investors have recently made changes to their positions in ASMB. Acadian Asset Management LLC grew its position in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 3,312 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Patient Square Capital LP acquired a new stake in shares of Assembly Biosciences in the third quarter valued at about $3,461,000. Finally, Palumbo Wealth Management LLC grew its position in Assembly Biosciences by 86.4% during the third quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 16,131 shares in the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.
About Assembly Biosciences
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.
Featured Stories
- Five stocks we like better than Assembly Biosciences
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
